TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
PSNL

Personalis Inc

Healthcare · Diagnostics & Research

16.40$ +1.0% vs. previous close Closing price · As of: Sep 18, 2026

Investor relations

Report Dates

Investor relations overview for Personalis Inc (PSNL): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 11/03/2026.

Next report 11/03/2026
Last report 08/04/2026
Earnings surprise by quarter (%)
Q3 23 · 7.7 % 23 Q4 23 · -8.0 % 23 Q1 24 · 31.6 % 24 Q2 24 · 36.8 % 24 Q3 24 · -88.2 % 24 Q4 24 · 12.9 % 24 Q1 25 · 28.0 % 25 Q2 25 · 4.2 % 25 Q3 25 · 11.1 % 25 Q4 25 · 16.1 % 25 Q1 26 · -3.6 % 26 Q2 26 · -20.0 % 26

EPS estimate beaten

Full history 19 of 30 quarters (63%)
Last 16 quarters 10 of 16 quarters (63%)

Earnings Call Transcripts

Search all transcripts →

  • 05/07/2026 Earnings Call Q1 2026 Open →
  • 02/26/2026 Earnings Call Q4 2025 Open →
  • 11/04/2025 Earnings Call Q3 2025 Open →
  • 08/05/2025 Earnings Call Q2 2025 Open →
  • 05/06/2025 Earnings Call Q1 2025 Open →
  • 02/27/2025 Earnings Call Q4 2024 Open →
  • 11/06/2024 Earnings Call Q3 2024 Open →
  • 08/07/2024 Earnings Call Q2 2024 Open →
  • 05/08/2024 Earnings Call Q1 2024 Open →

News on This Stock

  • 08/20/2026 Personalis, Inc. (PSNL): Other Events · sec.gov Open ↗
  • 08/04/2026 Personalis, Inc. (PSNL): Results of Operations and Financial Condition; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/20/2026 Personalis, Inc. (PSNL): Entry into a Material Definitive Agreement; Financial Statements and Exhibits · sec.gov Open ↗
  • 07/20/2026 Personalis, Inc. (PSNL): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits · sec.gov Open ↗

Automatically matched wire and portal stories; external links open the original source.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?